BlueWillow Biologics Announces Issuance of Intranasal Anthrax Vaccine Patent
BlueWillow Biologics® today announced the issuance of U.S. patent number 10,138,279 covering an intranasal NanoVax® anthrax vaccine. The patent, issued to the University of Michigan under exclusive license to BlueWillow, is based on research conducted by the University demonstrating the vaccine’s ability to elicit long-term protection against lethal anthrax challenge in animals. BlueWillow’s intranasal NanoVax platform … Continued